Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Amneal Pharmaceuticals, Inc. (AMRX)

2.32   -0.09 (-3.73%) 12-07 16:00
Open: 2.4 Pre. Close: 2.41
High: 2.475 Low: 2.27
Volume: 3,036,800 Market Cap: 351(M)

Technical analysis

as of: 2022-12-07 4:20:17 PM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 3.08     One year: 3.6
Support: Support1: 2.23    Support2: 1.98
Resistance: Resistance1: 2.64    Resistance2: 3.08
Pivot: 2.38
Moving Average: MA(5): 2.42     MA(20): 2.37
MA(100): 2.49     MA(250): 3.4
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 43.2     %D(3): 51.5
RSI: RSI(14): 48.7
52-week: High: 5.13  Low: 1.95
Average Vol(K): 3-Month: 1,005 (K)  10-Days: 1,501 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AMRX ] has closed above bottom band by 38.5%. Bollinger Bands are 10.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.48 - 2.49 2.49 - 2.5
Low: 2.24 - 2.25 2.25 - 2.26
Close: 2.3 - 2.33 2.33 - 2.35

Company Description

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Headline News

Mon, 05 Dec 2022
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Short Interest Down 7.9% in November - MarketBeat

Wed, 23 Nov 2022
Amneal to Participate at Upcoming Investor Conferences | News | - The Bakersfield Californian

Tue, 22 Nov 2022
Amneal Pharmaceuticals (AMRX) Launches RELEUKO in the US -

Mon, 14 Nov 2022
Is Amneal Pharmaceuticals Inc (AMRX) Stock a Smart Value? - InvestorsObserver

Fri, 11 Nov 2022
FDA accepts Amneal Pharmaceuticals NDA for Parkinson's drug IPX203 (NYSE:AMRX) - Seeking Alpha

Fri, 04 Nov 2022
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 151 (M)
Shares Float 97 (M)
% Held by Insiders 10.8 (%)
% Held by Institutions 66.8 (%)
Shares Short 4,680 (K)
Shares Short P.Month 4,700 (K)

Stock Financials

EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.96
Profit Margin (%) -6.2
Operating Margin (%) 7.5
Return on Assets (ttm) 2.5
Return on Equity (ttm) -87.6
Qtrly Rev. Growth 3.2
Gross Profit (p.s.) 5.17
Sales Per Share 14.12
EBITDA (p.s.) 2.65
Qtrly Earnings Growth 0
Operating Cash Flow 152 (M)
Levered Free Cash Flow 217 (M)

Stock Valuations

PE Ratio 233
PEG Ratio -0.3
Price to Book value 1.18
Price to Sales 0.16
Price to Cash Flow 2.32

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.